A Phase 3 interventional study of Roflumilast Cream 0.15% and Vehicle Cream in Atopic Dermatitis Eczema, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 49 sites in 2 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.
Sponsored by Arcutis Biotherapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing roflumilast in Dermatitis, Atopic — 4 open to participants now, 4 under way, 1 of them phase 3. Roflumilast · Dermatitis, Atopic.
Among the 13 studies testing roflumilast in Dermatitis, Atopic, this one is the 3rd largest by enrollment, is one of 4 that started in 2021, is one of 6 in phase 3, and was the 4th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 13 studies testing roflumilast in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Integrative Skin Science and Research · Sites in United States
Ages 12+
Nora Mohamed Abdelrazik · Sites in Egypt
Ages 12+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 654 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 136 across the 13 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 6 most frequent:
Arcutis Biotherapeutics, Inc. is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 20 (83%) have results posted.
Arcutis Biotherapeutics, Inc. has 9 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
1 of the studies testing roflumilast in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07560618Integrative Skin Science and ResearchObtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream. | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing roflumilast in Dermatitis, Atopic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a parallel group, double blind, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-151) cream vs vehicle applied once daily (qd) for 4 weeks by participants with atopic dermatitis (eczema).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with mild to moderate AD apply roflumilast cream 0.15% QD for 4 weeks.
Drug: Roflumilast Cream 0.15%
Participants with mild to moderate AD applied vehicle cream QD for 4 weeks.
Drug: Vehicle Cream
Roflumilast Cream 0.15% - Active
Also known as: ARQ-151
Cream - Vehicle
Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4
The percentage of participants achieving vIGA-AD "success" is presented with multiple imputation of missing observations. vIGA-AD "success" is defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear), with higher scores indicative of greater symptom severity.
Time frame: Week 4
Achievement of vIGA-AD Success at Week 4 in Participants With "Moderate" Baseline Scores
The percentage of participants with moderate baseline scores achieving vIGA-AD "success" is presented with multiple imputation of missing observations. vIGA-AD "success" is defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline in participants with a 'moderate' baseline vIGA-AD score. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.
Time frame: Week 4
Achievement of a 4-Point Reduction in the Average, Weekly Worst Itch Numeric Rating Scale (WI-NRS) at Week 4 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4
The percentage of participants ≥12 years of age with a baseline WI-NRS ≥4 achieving WI-NRS success at Week 4 is presented with multiple imputation of missing observations. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participant experienced in the previous 24 hours (higher scores indicate higher itch severity).
Time frame: Week 4
Achievement of a 4-Point Reduction in the Average, Weekly WI-NRS at Week 2 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4
The percentage of participants ≥12 years of age with a baseline WI-NRS ≥4 achieving WI-NRS success at Week 2 is presented with multiple imputation of missing observations. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participant experienced in the previous 24 hours (higher scores indicate higher itch severity).
Time frame: Week 2
Achievement of a 4-Point Reduction in the Average, Weekly WI-NRS at Week 1 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4
The percentage of participants ≥12 years of age with a baseline WI-NRS ≥4 achieving WI-NRS success at Week 1 is presented with multiple imputation of missing observations. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participant experienced in the previous 24 hours (higher scores indicate higher itch severity).
Time frame: Week 1
Achievement of ≥ 75% Reduction in the Eczema Area and Severity Index (EASI-75) at Week 4
The percentage of participants achieving EASI-75 is presented with multiple imputation of missing observations. EASI-75 is a ≥75% reduction from the baseline EASI score. EASI combines the assessment of the severity of lesions and the area affected into a single total score in the range 0 (no disease) to 72 (maximal disease). To calculate the EASI, the sum of the severity rating (0 to 3 with 3 being the most severe) for four clinical signs are multiplied with the numerical value of the area affected and with the percentage of the four body areas.
Time frame: Week 4
Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 4
The percentage of participants scoring 'clear' or 'almost clear' on vIGA-AD at Week 4 is presented with multiple imputation of missing observations. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.
Time frame: Week 4
Achievement of vIGA-AD Success at Week 2
The percentage of participants achieving "success" on the VIGA-AD at Week 2 is presented with multiple imputation of missing observations. vIGA-AD "success" is defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.
Time frame: Week 2
Achievement of vIGA-AD Success at Week 1
The percentage of participants achieving "success" on the VIGA-AD at Week 1 is presented with multiple imputation of missing observations. vIGA-AD "success" is defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.
Time frame: Week 1
Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 2
The percentage of participants scoring 'clear' or 'almost clear' on vIGA-AD at Week 4 is presented with multiple imputation of missing observations. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.
Time frame: Week 2
Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 1
The percentage of participants scoring 'clear' or 'almost clear' on vIGA-AD at Week 4 is presented with multiple imputation of missing observations. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.
Time frame: Week 1
This study was conducted at 65 centers in the United States, Canada, and Poland.
| Milestone | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|
| Started | 433 | 221 |
| Completed | 404 | 208 |
| Not completed | 29 | 13 |
| Withdrew: Lost to follow-up | 11 | 3 |
| Withdrew: Adverse event | 6 | 3 |
| Withdrew: Lack of efficacy | 5 | 2 |
| Withdrew: Withdrawal by subject | 4 | 5 |
| Withdrew: Noncompliance | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Consent withdrawn due to aes of nausea, headaches, dizziness, and brain fog | 1 | 0 |
The percentage of participants achieving vIGA-AD "success" is presented with multiple imputation of missing observations. vIGA-AD "success" is defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear), with higher scores indicative of greater symptom severity.
| percentage of participants | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|
| Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 | 32.0 (27.79 to 36.63) | 15.2 (11.06 to 20.64) |
The percentage of participants with moderate baseline scores achieving vIGA-AD "success" is presented with multiple imputation of missing observations. vIGA-AD "success" is defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline in participants with a 'moderate' baseline vIGA-AD score. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.
| percentage of participants | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|
| Achievement of vIGA-AD Success at Week 4 in Participants With "Moderate" Baseline Scores | 35.0 (29.97 to 40.36) | 17.5 (12.38 to 24.13) |
The percentage of participants ≥12 years of age with a baseline WI-NRS ≥4 achieving WI-NRS success at Week 4 is presented with multiple imputation of missing observations. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participant experienced in the previous 24 hours (higher scores indicate higher itch severity).
| percentage of participants | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|
| Achievement of a 4-Point Reduction in the Average, Weekly Worst Itch Numeric Rating Scale (WI-NRS) at Week 4 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4 | 33.6 (28.19 to 39.41) | 20.7 (14.61 to 28.58) |
The percentage of participants ≥12 years of age with a baseline WI-NRS ≥4 achieving WI-NRS success at Week 2 is presented with multiple imputation of missing observations. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participant experienced in the previous 24 hours (higher scores indicate higher itch severity).
| percentage of participants | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|
| Achievement of a 4-Point Reduction in the Average, Weekly WI-NRS at Week 2 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4 | 23.8 (19.14 to 29.24) | 9.8 (5.79 to 16.03) |
The percentage of participants ≥12 years of age with a baseline WI-NRS ≥4 achieving WI-NRS success at Week 1 is presented with multiple imputation of missing observations. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participant experienced in the previous 24 hours (higher scores indicate higher itch severity).
| percentage of participants | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|
| Achievement of a 4-Point Reduction in the Average, Weekly WI-NRS at Week 1 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4 | 9.5 (6.60 to 13.60) | 2.3 (0.77 to 6.41) |
The percentage of participants achieving EASI-75 is presented with multiple imputation of missing observations. EASI-75 is a ≥75% reduction from the baseline EASI score. EASI combines the assessment of the severity of lesions and the area affected into a single total score in the range 0 (no disease) to 72 (maximal disease). To calculate the EASI, the sum of the severity rating (0 to 3 with 3 being the most severe) for four clinical signs are multiplied with the numerical value of the area affected and with the percentage of the four body areas.
| percentage of participants | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|
| Achievement of ≥ 75% Reduction in the Eczema Area and Severity Index (EASI-75) at Week 4 | 43.2 (38.54 to 47.94) | 22.0 (16.97 to 28.04) |
The percentage of participants scoring 'clear' or 'almost clear' on vIGA-AD at Week 4 is presented with multiple imputation of missing observations. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.
| percentage of participants | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|
| Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 4 | 41.5 (36.93 to 46.25) | 25.2 (19.91 to 31.41) |
The percentage of participants achieving "success" on the VIGA-AD at Week 2 is presented with multiple imputation of missing observations. vIGA-AD "success" is defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.
| percentage of participants | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|
| Achievement of vIGA-AD Success at Week 2 | 21.2 (17.57 to 25.33) | 6.4 (3.84 to 10.44) |
The percentage of participants achieving "success" on the VIGA-AD at Week 1 is presented with multiple imputation of missing observations. vIGA-AD "success" is defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.
| percentage of participants | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|
| Achievement of vIGA-AD Success at Week 1 | 8.1 (5.87 to 11.03) | 0.5 (0.08 to 2.52) |
The percentage of participants scoring 'clear' or 'almost clear' on vIGA-AD at Week 4 is presented with multiple imputation of missing observations. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.
| percentage of participants | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|
| Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 2 | 31.8 (27.58 to 36.38) | 13.6 (9.72 to 18.79) |
The percentage of participants scoring 'clear' or 'almost clear' on vIGA-AD at Week 4 is presented with multiple imputation of missing observations. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity.
| percentage of participants | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|
| Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 1 | 14.3 (11.33 to 17.93) | 5.9 (3.47 to 9.80) |
Collected over Up to approximately 29 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roflumilast Cream 0.15% | 0/433 (0%) | 4/433 (0.9%) | 0/433 (0%) |
| Vehicle Cream | 0/221 (0%) | 0/221 (0%) | 0/221 (0%) |
| Event | Roflumilast Cream 0.15% | Vehicle Cream |
|---|---|---|
| DiverticulitisInfections and infestations | 1/433 | 0/221 |
| DepressionPsychiatric disorders | 1/433 | 0/221 |
| Suicidal ideationPsychiatric disorders | 1/433 | 0/221 |
| Pulmonary embolismVascular disorders | 1/433 | 0/221 |
| Age, Continuous(years) | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|
| Mean | 28.1 ± 19.14 | 28.5 ± 18.94 | 28.2 ± 19.06 |
| Sex: Female, Male(Participants) | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|
| Female | 237 | 129 | 366 |
| Male | 196 | 92 | 288 |
| Ethnicity (NIH/OMB)(Participants) | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|
| Hispanic or Latino | 99 | 56 | 155 |
| Not Hispanic or Latino | 333 | 164 | 497 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|
| White | 261 | 129 | 390 |
| American Indian or Alaska native | 2 | 0 | 2 |
| Asian | 63 | 32 | 95 |
| Native Hawaiian or other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 80 | 46 | 126 |
| Multiple | 12 | 6 | 18 |
| Other | 14 | 8 | 22 |
| Randomization validated Investigator's Global Assessment Scale for Atopic Dermatitis (vIGA-AD)(Participants) | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|
| 2 - Mild | 105 | 57 | 162 |
| 3 - Moderate | 328 | 164 | 492 |
| Verified vIGA-AD(Participants) | Roflumilast Cream 0.15% | Vehicle Cream | Total |
|---|---|---|---|
| Mild | 103 | 59 | 162 |
| Moderate | 330 | 162 | 492 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2021 to primary completion in Aug 2022, 19 months.
Results were first posted in Oct 2024, 2 years 1 month after primary completion. A results delay was requested in Jul 2023.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 19 months is close to that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast
Arcutis Biotherapeutics, Inc. →